TAD After Chemotherapy in Locally Advanced Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospital Universitari de Bellvitge
About this trial
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Eligibility criteria
Qualifiers
Axillary lymph node metastasis proven by cytology
Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
Neoadjuvant chemotherapy
Disqualifiers
cN3 verified by imaging tests
N2 due to internal mammary involvement (N2b).
Tumors whose surrogate molecular subtype is luminal A.
Patients undergoing neoadjuvant endocrine therapy
Trial design
Treatments tested in this trial
- Target Axillary Dissection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov